Pharma and Healthcare

Stirling Health
Stirling Health has an established, specialised sales team servicing Australian pharmacies nationally.
About Stirling Health


Nature's Firewall
Nature's Firewall has been established in North America to market the Company's joint ventured botanical products and other selected products by direct Internet marketing and through selected retail establishments.
About Nature's Firewall

 
Botanical Products

The Stirling Botanical Product Range


Manufacturing
Stirling Products Limited owns a modern new high-tech pharmaceutical manufacturing facility in Cape Breton, Canada through which the Company will provide contract manufacturing services as well manufacture its own products.

The current fit-out and configuration of the plant provides for an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product.

All inquiries for the contract manufacture of pharmacetical product please contact
pharma@stirlingproducts.net


Research and Development

Drug Delivery Platform

Initial validation and independent testing of drug administration using prototype demonstration devices has shown the Company's joint ventured High Density Aerosol ("HDA") technology to be highly efficient and effective in delivering drugs via inhalation. A major benefit of HDA drug administration is that it promises to provide the same efficacy as drugs taken orally, with far less active drug content which, subject to formal trial validation, should therefore increase drug safety and substantially lessen any side effects. The initial primary objective will be the substantiation of equivalency to other inhalation devices for the use of respiratory products.

Find out more


Animal Products

R-Salbutamol

R-Salbutamol growth agents are classic metabolic modifiers that at very low doses, convert energy normally used for fat production into energy for meat production.

The Intellectual Property which forms the basis of Stirling 's technology revolves around a pharmaceutical called R-Salbutamol. R-Salbutamol is a purified version of the compound salbutamol (also known as albuterol) which has worldwide acceptance for the treatment of respiratory disease.

Salbutamol has two mirror image chemical molecular components (enantiomers). Purifying this mixture of enantiomers to a product containing only a single enantiomer (the R enantiomer) has several advantages, including a reduction of adverse effects c au sed by the unwanted enantiomer and preventing the interference with the favourable effects of the active enantiomer.

In human pharmaceutical markets, industry pressure to switch to pure enantiomer drugs started in the 1980s led by companies looking for patent extension to drugs that were due to have their patents expire. Regulatory agencies supported this trend as the resultant "new" drugs were of higher purity with fewer side effects. The percentage of total sales of these "new" drugs has grown from less than 10% of the total pharmaceutical market in 1985, to 25% in 1995 and are now at well over 40%.

Peter Boonen
Managing Director
Mr. Boonen has over 30 years experience in the investment and equity markets and he has an extensive working knowledge of the pharmaceutical industry and particularly of the Company's core and joint venture products. Mr. Boonen is also the Managing Director of Zodiac Capital Limited, a Sydney based publicly listed investment group, with which Stirling Products has joint ventured its range of botanical products and its inhalation drug technology platform. Through this dual management role Mr. Boonen will guide and manage the commercialization of the products in the interests of the two partners.
 
Neil Covey
Executive Director of Sales & Marketing
Mr Covey, former Head of Sales and Marketing for Bayer (Australia) has a strong depth of expertise in international sales and management in the pharmaceutical and healthcare market. His previous experience includes senior sales, marketing and business development roles with companies including Astra and Knoll Pharmaceuticals. His senior management positions have included leadership roles in international marketing and project management in Europe and Asia. Neil has been responsible for the successful launch of many well known brands into the ethical, hospital, pharmacy and consumer segments of the healthcare industry.
 
Gulshan Jugroo
Executive Director
Mr Jugroo graduated with an Honours in Accounting (Major) and Business Information Systems (Minor) from the Middlesex University in the UK and holds a Masters of Business in Accounting from Victoria University in Melbourne , specialising in corporate forensic accounting. Mr Jugroo is the Company Secretary of a number of public companies and has previously held accounting appointments in Australia , Mauritius and the UK .

Michael Kean
CFO
Michael is a CPA, has a Bachelor of Business Degree with First Class Honours from the University of Technology in Sydney and a Graduate Certificate of Risk Management from Monash University.  He further has distinction certificates in Microcomputing, Marketing Management and a sub-major in Computer Science. Michael has held positions as a tutor at the University of Technology in Sydney and as a Senior Researcher in fields including the Financial Reporting of Intangible Assets, Executive Remuneration, Voluntary Disclosure and Australian R & D.  Most recently Michael over a nine-year period at ORIX Australia Corporation Ltd held roles in Corporate Management Accounting, Financial Accounting, Accounting Systems Support & Development, Internal Auditing, Risk Management and Compliance.

Professor Glyn M Tonge
PhD, DUniv, FRSM, Non Executive Director
Professor Tonge has extensive experience in the international pharmaceutical, healthcare and financial services industries. He was previously a research manager at ICI (now AstraZeneca) and with PA Consulting Group he spent a number of years in the US, Malaysia, Indonesia and Japan advising governments on healthcare & natural resources. In the 90s he was a director of Baring Brothers & Co Ltd, Baring Brothers International Ltd and ING Barings where he was global head of pharmaceuticals and healthcare and a director in corporate finance. During this period he was involved in setting up a new healthcare and life sciences venture fund with ING Barings, a German investment bank and Boehringer Mannheim (now Roche) as well as numerous M & A and IPO transactions internationally. He is a Fellow of the Royal Institution in 2004 and a Fellow of the Royal College of Medicine in 2005 and he was appointed as an advisor to the UK Ministry of Defence Scientific Advisory Board in 2006. He is a Liveryman and Freeman in the City of London.

John Diasinos
Company Secretary
Mr John Diasinos has experience in all facets of Company Secretariat, Corporate Governance, Compliance and Risk Management having worked for a number of listed entities. His most recent role before joining Stirling Products Ltd was at Trust Company Limited where he was administering the risk management in their responsible entity division for a portfolio of 14 client managed investment schemes (listed and unlisted) with over $4 billion in total fund assets. Mr Diasinos is a Fellow member of the Chartered Institute of Secretaries, Member of the National Institute of Accountants and holds a Master of Commercial Law and a Justice of the Peace.